ArticleEndocrine, metabolic & immune disorders drug targets2026
Relationship Between Comprehensive Inflammatory Indicators and Gout Risk: A Cross-sectional Study Based on NHANES 2015-2018.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGout development and progression are closely linked to inflammatory processes. Six novel systemic inflammation indices, including the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), inflammation score, systemic inflammation response index (SIRI), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) have shown significant value in assessing systemic inflammation severity and related comorbidities. This study aims to explore the relationship between these systemic inflammation indices and the risk of gout.
methodsData from the 2015-2018 National Health and Nutrition Examination Survey (NHANES) were analyzed in this study to explore the link between systemic inflammation indices and gout risk. Demographic information of all participants was collected, and multivariable logistic regression was applied to evaluate the relationship between the inflammation indices and gout risk. Restricted cubic splines (RCS) were used to investigate the nonlinear association between inflammation scores and gout risk. Stratified and interaction analyses were also conducted to examine the relationships in different populations.
resultsA total of 7,681 participants were included in the analysis. After adjusting for all covariates in the multivariable logistic regression model, the inflammation score demonstrated the most significant association with gout risk. Further RCS analysis revealed a nonlinear relationship (P=0.0134) with a turning point at 1.641. When the inflammation score was below 1.641, an increase in the score was significantly associated with a higher risk of gout. Stratified analyses indicated that age, race, and smoking status interacted with the relationship between inflammation scores and gout risk. DISCUSSION: This study identified a significant association between the inflammation score and gout risk, particularly at low-to-moderate inflammation levels, suggesting that systemic inflammation may play an important role in the early stages of gout development. The inflammation score remained independently associated with gout after full adjustment, indicating its potential utility for early risk identification.
conclusionThe findings suggest that the inflammation score is a robust and independent predictor of gout risk, particularly at low-to-moderate levels, highlighting its potential for the early identification of high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.